Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Onyx Biotec IPO is a book built issue of Rs 29.34 crores. The issue is entirely a fresh issue of 48.1 lakh shares.
Onyx Biotec IPO opens for subscription on November 13, 2024 and closes on November 18, 2024. The allotment for the Onyx Biotec IPO is expected to be finalized on Tuesday, November 19, 2024. Onyx Biotec IPO will list on NSE SME with tentative listing date fixed as Thursday, November 21, 2024.
Onyx Biotec IPO price band is set at ₹58 to ₹61 per share. The minimum lot size for an application is 2000 Shares. The minimum amount of investment required by retail investors is ₹122,000. The minimum lot size investment for HNI is 2 lots (4,000 shares) amounting to ₹244,000.
Horizon Management Private Limited is the book running lead manager of the Onyx Biotec IPO, while Mas Services Limited is the registrar for the issue. The market maker for Onyx Biotec IPO is Giriraj Stock Broking.
Refer to Onyx Biotec IPO RHP for detailed information.
| IPO Date | November 13, 2024 to November 18, 2024 |
| Listing Date | [.] |
| Face Value | ₹10 per share |
| Price Band | ₹58 to ₹61 per share |
| Lot Size | 2000 Shares |
| Total Issue Size | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Fresh Issue | 4,810,000 shares (aggregating up to ₹29.34 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
| Share holding pre issue | 13,322,200 |
| Share holding post issue | 18,132,200 |
| Market Maker portion | 244,000 shares Giriraj Stock Broking |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not more than 49.89% of the Net Issue |
| Retail Shares Offered | Not less than 35.04% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15.07% of the Net Issue |
Onyx Biotec IPO raises Rs 8.33 crore from anchor investors. Onyx Biotec IPO Anchor bid date is November 12, 2024. Onyx Biotec IPO Anchor Investors list
| Bid Date | November 12, 2024 |
| Shares Offered | 1,366,000 |
| Anchor Portion Size (In Cr.) | 8.33 |
| Anchor lock-in period end date for 50% shares (30 Days) | December 19, 2024 |
| Anchor lock-in period end date for remaining shares (90 Days) | February 17, 2025 |
Onyx Biotec IPO opens on November 13, 2024, and closes on November 18, 2024.
| IPO Open Date | Wednesday, November 13, 2024 |
| IPO Close Date | Monday, November 18, 2024 |
| Basis of Allotment | Tuesday, November 19, 2024 |
| Initiation of Refunds | Wednesday, November 20, 2024 |
| Credit of Shares to Demat | Wednesday, November 20, 2024 |
| Listing Date | Thursday, November 21, 2024 |
| Cut-off time for UPI mandate confirmation | 5 PM on November 18, 2024 |
Investors can bid for a minimum of 2000 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2000 | ₹122,000 |
| Retail (Max) | 1 | 2000 | ₹122,000 |
| HNI (Min) | 2 | 4,000 | ₹244,000 |
| Lot Size Calculator | |||
The Promoters of the company are Sanjay Jain, Naresh Kumar and Fateh Pal Singh.
| Share Holding Pre Issue | 88.60% |
| Share Holding Post Issue |
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.
Onyx Biotec Limited's revenue increased by 35.99% and profit after tax (PAT) rose by 64.35% between the financial year ending with March 31, 2024 and March 31, 2023.
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
| Assets | 7,476.57 | 7,413.58 | 5,872.36 | 3,683.84 |
| Revenue | 1,054.11 | 5,387.43 | 3,961.65 | 4,498.09 |
| Profit After Tax | 130.77 | 303.16 | 184.46 | 335.29 |
| Net Worth | 2,618.64 | 2,487.87 | 1,820.16 | 1,637.59 |
| Reserves and Surplus | 1,286.42 | 1,155.65 | 1,230.00 | 1,047.43 |
| Total Borrowing | 3,156.14 | 3,078.04 | 2,922.83 | 1,224.39 |
| Amount in ₹ Lakhs | ||||
The market capitalization of Onyx Biotec IPO is Rs 110.61 Cr.
KPI as of May 31, 2024.
| KPI | Values |
|---|---|
| ROE | 4.99% |
| ROCE | 3.71% |
| Debt/Equity | 1.21 |
| RoNW | 4.99% |
| P/BV | 3.1 |
| PAT Margin (%) | 12.42 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 2.28 | 4.33 |
| P/E (x) | 26.81 | 14.1 |
The Company proposes to utilize the Net Proceeds from the Issue towards the following objects:
[Dilip Davda] The company is engaged in a highly competitive and fragmented segment of sterile water, dry power-syrup products. It marked inconsistency in its top lines for the reported periods. Highly fluctuating bottom lines raises eyebrows. Based on FY25 super earnings, the issue appears fully priced. Well-informed investors may park moderate funds for long term. Read detail review...
Onyx Biotec Limited
Bir Plassi Near Sainimajraropar,
Nalagarh Road
District Solan – 174101,
Phone: +91 172 265 6384
Email: generalinfo@onyxbiotec.com
Website: http://www.onyxbiotec.com/
Mas Services Limited
Phone: (011) 2610 4142
Email: ipo@masserv.com
Website: https://www.masserv.com/opt.asp
SME Company Owners
We could help you get listed on the stock market.
Check our SME IPO Guide 
Onyx Biotec IPO is a SME IPO of 4,810,000 equity shares of the face value of ₹10 aggregating up to ₹29.34 Crores. The issue is priced at ₹58 to ₹61 per share. The minimum order quantity is 2000 Shares.
The IPO opens on November 13, 2024, and closes on November 18, 2024.
Mas Services Limited is the registrar for the IPO. The shares are proposed to be listed on NSE SME.
Zerodha customers can apply online in Onyx Biotec IPO using UPI as a payment gateway. Zerodha customers can apply in Onyx Biotec IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Onyx Biotec IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Onyx Biotec IPO opens on November 13, 2024 and closes on November 18, 2024.
Onyx Biotec IPO lot size is 2000 Shares, and the minimum amount required is ₹122,000.
You can apply in Onyx Biotec IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Onyx Biotec IPO will be done on Tuesday, November 19, 2024, and the allotted shares will be credited to your demat account by Wednesday, November 20, 2024. Check the Onyx Biotec IPO allotment status.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
